Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron

Abstract The continuing evolution of SARS-CoV-2 variants challenges the durability of existing spike (S)-based COVID-19 vaccines. We hypothesized that vaccines composed of both S and nucleocapsid (N) antigens would increase the durability of protection by strengthening and broadening cellular immuni...

Full description

Saved in:
Bibliographic Details
Main Authors: Paolla Beatriz Almeida Pinto, Julia Timis, Kantinan Chuensirikulchai, Qin Hui Li, Hsueh Han Lu, Erin Maule, Michael Nguyen, Rúbens Prince dos Santos Alves, Shailendra Kumar Verma, Fernanda Ana-Sosa-Batiz, Kristen Valentine, Sara Landeras-Bueno, Kenneth Kim, Kathryn Hastie, Erica Ollmann Saphire, Ada Alves, Annie Elong Ngono, Sujan Shresta
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-024-01043-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The continuing evolution of SARS-CoV-2 variants challenges the durability of existing spike (S)-based COVID-19 vaccines. We hypothesized that vaccines composed of both S and nucleocapsid (N) antigens would increase the durability of protection by strengthening and broadening cellular immunity compared with S-based vaccines. To test this, we examined the immunogenicity and efficacy of wild-type SARS-CoV-2 S- and N-based DNA vaccines administered individually or together to K18-hACE2 mice. S, N, and S + N vaccines all elicited polyfunctional CD4+ and CD8+ T cell responses and provided short-term cross-protection against Beta and Omicron BA.2 variants, but only co-immunization with S + N vaccines provided long-term protection against Omicron BA.2. Depletion of CD4+ and CD8+ T cells reduced the long-term efficacy, demonstrating a crucial role for T cells in the durability of protection. These findings underscore the potential to enhance long-lived protection against SARS-CoV-2 variants by combining S and N antigens in next-generation COVID-19 vaccines.
ISSN:2059-0105